Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 6/20 | 0.38 |
| ▸ | CRY1 | Q16526 | 6/20 | 0.38 |
| ▸ | CRY2 | Q49AN0 | 6/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908881 | 0.89 | PER2 (0.36) | PER2CRY1CRY2PDK2PDCD1 | |
| SCHEMBL1908746 | 0.83 | PER2 (0.36) | PER2CRY1CRY2 | |
| SCHEMBL12228957 | 0.79 | PER2 (0.43) | PER2CRY1CRY2 | |
| SCHEMBL12251949 | 0.77 | PER2 (0.34) | PER2CRY1CRY2PDK2 | |
| SCHEMBL8238343 | 0.74 | PER2 (0.35) | PER2CRY1CRY2 | |
| SCHEMBL731034 | 0.74 | PER2 (0.35) | PER2CRY1CRY2PDK2 | |
| SCHEMBL17575508 | 0.73 | PSEN1 (0.33) | PER2CRY1CRY2PDCD1CD274 | |
| SCHEMBL10064352 | 0.72 | ALOX15 (0.35) | PER2CRY1CRY2PDK2 | |
| SCHEMBL5618249 | 0.72 | PER2 (0.34) | PER2CRY1CRY2PDK2 | |
| SCHEMBL2814302 | 0.72 | PER2 (0.37) | PER2CRY1CRY2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | PER2 350/4885CRY1 1391/4885CRY2 1925/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | PER2 4309/4885CRY1 2168/4885CRY2 3001/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | PER2 2204/4885CRY1 2692/4885CRY2 2747/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | PER2 3834/4885CRY1 2602/4885CRY2 3323/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | PER2 2627/4885CRY1 2971/4885CRY2 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.